Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm NCT07343479

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

A Clinical Study of Sac-TMT for Injection Combined With Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) ± Radiotherapy in Subjects With EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer and Brain Metastasis Who Have Failed Prior EGFR-TKI Treatment

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Conditions Brain Metastasis EGFR Gene Mutations NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions sac-TMT plus EGFR-TKI

Updated 1 time since 2026 Last updated: Jan 6, 2026 Started: May 1, 2026 Primary completion: Jun 20, 2027 Completion: Dec 20, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Brain Metastasis and EGFR Gene Mutations, this trial is actively recruiting participants. The trial is conducted by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and has accumulated 1 data snapshot since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

1 version recorded

Not Yet Recruiting — PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Zhejiang Cancer Hospital

Data source: Zhejiang Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China